Department of Drug and Health Sciences, V.le A. Doria, 6, 95125 Catania, Italy
Office: +39 095/7384223

Month: January 2024

TBValid Collection: Tuberculosis data

We take immense pride in presenting the application brief for #tuberculosis treatment, “TBValid collection: Tuberculosis data,” utilizing UISS-TB, an in silico trial solution employing agent-based modeling. “The creation of a synthetically generated, fully anonymized data collection from real-world sources is pivotal for advancing in silico trials targeting crucial factors in silico trials of antivancing in…
Read more

Breaking Ground: The Combine Group’s Latest Venture in Novel Immunotherapies for Tuberculosis and Mycobacterial Diseases

The Combine Group is delighted to announce our involvement in yet another project funded under the Horizon Europe Program: Novel Immunotherapies for Tuberculosis and other Mycobacterial Diseases (ITHEMYC) ???? This venture is a significant opportunity to apply innovative solutions in silico modelling to facilitate both in vitro and in vivo preclinical progression and predict the…
Read more

Combine Group on “La Sicilia”

Evading or minimizing animal testing, expediting drug approval processes, and navigating research pitfalls are the focal points of a team of researchers from the University of Catania, utilizing Uiss, the virtual patient. Uiss, an acronym for Universal Immune System Simulator, represents the culmination of fifteen years of work by Catania’s scientists and fits seamlessly into…
Read more

Diphtheria-tetanus-pertussis vaccine has positive effects against Covid-19

The diphtheria-tetanus-pertussis vaccine may have beneficial effects by against Sars-CoV-2 and Covid-19 disease. The study was carried out, using the immune system simulator called Universal Immune System Simulator (UISS), by the ‘Combine’ research group directed by Prof. Francesco Pappalardo of the Department of Drug and Health Sciences at the University of Catania and was recently…
Read more